Amarin Corp Plc (AMRN)

[retinadoc]

My letter to STAT News:

I am sure that STAT will agree that the integrity and credibility of any publication depends on issuing a correction when data proves past articles to be in error. In the case of of Amarin's drug Vascepa, there have been no less than 10 articles in 4 years that have questioned this life saving treatment for CV event prevention and argued that the results seen in Reduce-It, that led to its FDA approval, were an artifact of its mineral oil placebo.

We now have definitive confirmation that the drug is indeed effective in decreasing CV risk and the mineral oil hypothesis was the creation of a disgruntled aging academic, embarrassed by leading a failed competing trial.

Without a correction, STAT is fully complicit with a campaign of fear and doubt that has repeatedly discredited pure EPA and limited its adoption for CV patients. It is not hyperbole to suggest that this has cost lives. Pure EPA may have treatment indications that include COVID-19, oncology, and ALZs, so it is imperative that STAT now end spreading disinformation and publish a factual article on the results of Respect-EPA presented at AHA last week. If Mr. Herper is incapable of being objective, I suggest you assign another reporter to do the research and write the story.